<DOC>
	<DOC>NCT01143740</DOC>
	<brief_summary>This open-label study will evaluate efficacy, safety and tolerability of RO5045337 in patients with liposarcoma who are eligible for debulking surgery. Prior to surgery, patients will receive 2-3 cycles of RO5045337, orally for 10 days followed by 18 days of rest per cycle. Anticipated time on study treatment is 3 months. Patients with an incomplete resection may be treated for an additional 3 cycles with RO5045337.</brief_summary>
	<brief_title>A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery</brief_title>
	<detailed_description />
	<mesh_term>Liposarcoma</mesh_term>
	<criteria>adult patients, &gt;/=18 years of age well differentiated and/or dedifferentiated liposarcoma eligible for tumor debulking surgery willing to undergo tumor biopsies before, during and after treatment ECOG performance status 01 previous chemotherapy and/or radiation for liposarcoma; previous debulking surgery is acceptable patients receiving any other agent or therapy to treat their malignancy patients requiring anticoagulant therapy and/or antiplatelet therapy preexisting gastrointestinal disorders which may interfere with absorption of drugs history of seizure disorders or unstable CNS metastases clinically significant cardiovascular disease history of long QT syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>